Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Ohio State University Comprehensive Cancer Center
Abstract
This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas. Phase: PHASE1 Status: RECRUITING Conditions: Recurrent Malignant Glioma; Recurrent WHO Grade 3 Glioma; Recurrent WHO Grade 4 Glioma; WHO Grade 2 Glioma; WHO Grade 3 Glioma; WHO Grade 4 Glioma Interventions: Anti-GARP Chimeric Antigen Receptor-T Cells; Biospecimen Collection; Chest Radiography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Pheresis; Surgical Procedure